{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:03:33Z","timestamp":1789689813359,"version":"4.0.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mast cell disorders include mastocytosis and mast cell activation syndromes. Mastocytosis is a rare clonal disorder of the mast cell, driven by KIT D816V mutation in most cases. Mastocytosis is diagnosed and classified according to World Health Organization criteria. Mast cell activation syndromes encompass a diverse group of disorders and may have clonal or nonclonal etiologies. Hematologists may be consulted to assist in the diagnostic workup and\/or management of mast cell disorders. A consult to the hematologist for mast cell disorders may provoke anxiety due to the rare nature of these diseases and the management of nonhematologic mast cell activation symptoms. This article presents recommendations on how to approach the diagnosis and management of patients referred for common clinical scenarios.<\/jats:p>","DOI":"10.1182\/hematology.2022000366","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:20Z","timestamp":1670602400000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["How to evaluate the patient with a suspected mast cell disorder and how\/when to manage symptoms"],"prefix":"10.1182","volume":"2022","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"2","key":"2022120916094768400_hem2022000366C1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2022120916094768400_hem2022000366C2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"2022120916094768400_hem2022000366C3","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/ijms20122976","article-title":"Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2022120916094768400_hem2022000366C4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2022120916094768400_hem2022000366C5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1586\/17474086.2014.942280","article-title":"Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis","volume":"7","author":"Horny","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2022120916094768400_hem2022000366C6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","article-title":"Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group","volume":"10","author":"Hoermann","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2022120916094768400_hem2022000366C7","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/ijms22052586","article-title":"Molecular background, clinical features and management of pediatric mastocytosis: status 2021","volume":"22","author":"Lange","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2022120916094768400_hem2022000366C8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma and Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2022120916094768400_hem2022000366C9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin N Am"},{"issue":"7","key":"2022120916094768400_hem2022000366C10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"11","key":"2022120916094768400_hem2022000366C11","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"6","key":"2022120916094768400_hem2022000366C12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2022120916094768400_hem2022000366C13","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2022120916094768400_hem2022000366C14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"2022120916094768400_hem2022000366C15","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2022120916094768400_hem2022000366C16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2022120916094768400_hem2022000366C17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/modpathol.2012.199","article-title":"Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications","volume":"26","author":"Ryan","year":"2013","journal-title":"Mod Pathol"},{"issue":"6","key":"2022120916094768400_hem2022000366C18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2022120916094768400_hem2022000366C19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"2022120916094768400_hem2022000366C20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% +2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"2022120916094768400_hem2022000366C21","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","article-title":"Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022","volume":"10","author":"Butterfield","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2022120916094768400_hem2022000366C22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2","volume":"8","author":"Afrin","year":"2021","journal-title":"Diagnosis (Berl)"},{"issue":"8","key":"2022120916094768400_hem2022000366C23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"16","key":"2022120916094768400_hem2022000366C24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2022120916094768400_hem2022000366C25","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2022120916094768400_hem2022000366C26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2022120916094768400_hem2022000366C27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2022120916094768400_hem2022000366C28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"2022120916094768400_hem2022000366C29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.iac.2018.04.010","article-title":"Hymenoptera anaphylaxis as a clonal mast cell disorder","volume":"38","author":"Bonadonna","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"2022120916094768400_hem2022000366C30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"2022120916094768400_hem2022000366C31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2022120916094768400_hem2022000366C32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"2022120916094768400_hem2022000366C33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/ALN.0000000000000031","article-title":"Perioperative management of patients with mastocytosis","volume":"120","author":"Dewachter","year":"2014","journal-title":"Anesthesiology"},{"issue":"5","key":"2022120916094768400_hem2022000366C34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2017.05.021","article-title":"Management of mastocytosis in pregnancy: a review","volume":"5","author":"Lei","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2022120916094768400_hem2022000366C35","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2022120916094768400_hem2022000366C36","doi-asserted-by":"crossref","first-page":"AB336","DOI":"10.1016\/j.jaci.2019.12.062","article-title":"PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent or smoldering systemic mastocytosis (SM) with symptoms inadequately controlled by standard therapy","volume":"145","author":"Akin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2022120916094768400_hem2022000366C37","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"2022120916094768400_hem2022000366C38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2022120916094768400_hem2022000366C39","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2022120916094768400_hem2022000366C40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2022120916094768400_hem2022000366C41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2022120916094768400_hem2022000366C42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"2022120916094768400_hem2022000366C43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/55\/2021719\/55akin.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/55\/2021719\/55akin.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:48Z","timestamp":1670602428000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/55\/493495\/How-to-evaluate-the-patient-with-a-suspected-mast"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000366","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}